Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829347 · ClinicalTrials.gov registry record · Phase 3
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
A Phase 3 study, sponsored by Vital Therapies.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT01829347 is a Phase 3 study that was terminated before completion, run by Vital Therapies. The registered enrollment target is 18 participants.
The verdict
NCT01829347, a Phase 3 study, was terminated before completion, sponsored by Vital Therapies.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with the ELAD System is safe and effective in subjects with severe acute alcoholic hepatitis and Lille score failures (Lille score \>0.45).
Interventions
- BIOLOGICAL ELAD
- OTHER Standard of Care treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829347
The ClinicalTrials.gov registry entry for NCT01829347 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vital Therapies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ELAD is the first listed.
NCT01829347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829347 about?
NCT01829347 is a clinical study titled "To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure". The purpose of this study is to determine if treatment with the ELAD System is safe and effective in subjects with severe acute alcoholic hepatitis and Lille score failures (Lille score \>0.45).
What is the current status of trial NCT01829347?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2014-04. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01829347?
The interventions under investigation include: ELAD (BIOLOGICAL), Standard of Care treatment (OTHER).
Who is sponsoring clinical trial NCT01829347?
This trial is sponsored by Vital Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.